| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie |
2018-004590-27: Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia |
|
|
| Ongoing | 3 | 300 | Europe | cariprazine, RGH-188, Capsule, hard, Reagila | Gedeon Richter Plc, Gedeon Richter Plc | Adolescent patient (13-<18 years of age) with Schizophrenia, Adolescent patient (13-<18 years of age) with Schizophrenia, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-004006-26: Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia |
|
|
| Ongoing | 3 | 330 | Europe | cariprazine, RGH-188, Capsule, hard | Allergan Ltd, Allergan Ltd. | Adolescent Patients (13 to 17 years of age) with Schizophrenia, Adolescent Patients (13 to 17 years of age) with Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003164-31: The purpose of this study is to look into the safety and efficacy ofcariprazine as an add-on medication in the treatment of major depressivedisorder. |
|
|
| Not yet recruiting | 3 | 750 | RoW, Europe | Cariprazine, Capsule | Allergan Ltd., Allergan Sales LLC | Major Depressive Disorder, Clinical Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT04519099 / 2017-000818-34: Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia |
|
|
| Recruiting | 3 | 345 | Europe, US, RoW | Cariprazine, Placebo | Allergan, Allergan Ltd | Schizophrenia | 04/22 | 04/22 | | |
NCT05168007: Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia |
|
|
| Enrolling by invitation | 3 | 342 | RoW | WID-RGC20(Cariprazine) 3mg/day, WID-RGC20(Cariprazine) 6mg/day, Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day | Whanin Pharmaceutical Company | Schizophrenia | 07/23 | 07/23 | | |
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD |
|
|
| Recruiting | 3 | 152 | US | Cariprazine, VRAYLAR, AGN-241780, Placebo | AbbVie | Autism Spectrum Disorder | 10/24 | 11/24 | | |
NCT04777357: A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. |
|
|
| Recruiting | 3 | 380 | US, RoW | Cariprazine, Vraylar, Placebo | AbbVie | Depression, Bipolar I Disorder | 03/27 | 03/27 | | |
NCT03817502 / 2018-004006-26: Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia |
|
|
| Recruiting | 3 | 330 | Europe, US, RoW | Cariprazine, Placebo | Gedeon Richter Plc., Allergan Ltd. | Schizophrenia | 04/25 | 04/25 | | |
NCT05368558: Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia |
|
|
| Active, not recruiting | 3 | 34 | Japan, RoW | Cariprazine, VRAYLAR, Placebo | AbbVie | Schizophrenia | 10/24 | 10/24 | | |
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder |
|
|
| Recruiting | 3 | 280 | US | Cariprazine Flexible Dose | AbbVie | Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD) | 09/25 | 09/25 | | |
| Recruiting | 3 | 30 | Canada | Cariprazine, VRAYLAR®, Placebo | Jayasree Basivireddy | Bipolar I Disorder, Cognitive Impairment | 09/25 | 09/26 | | |
